Roussanka Kovatcheva

Roussanka Kovatcheva

Auto-generated profile, based on publicly available information

Roussanka Kovatcheva

Department of Endocrinology, Medical University of Sofia, University Hospital of Endocrinology, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Therapeutic Ultrasound
Verified
Journal Article
Open access
PDF file
RKRoussanka Kovatcheva
Roussanka Kovatcheva
JGJean-Noël Guglielmina
Jean-Noël Guglielmina
MAMarc Abehsera
Marc Abehsera
LBLoïc Boulanger
Loïc Boulanger
NLNicolas Laurent
Nicolas Laurent
EPEdouard Poncelet
Edouard Poncelet
The aim of our multicenter study was to assess the clinical outcome and safety of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) in patients with breast fibroadenoma (FA). From May 2011 to February 2013, 42 women with 51 FA in one or both breasts were selected for treatment with US-guided HIFU. Eight of 51 FA were treated twice. Patients’ age ranged from 16 to 52 years (mean 32 years). All patients with FA underwent core needle biopsy with histological confirmation. HIFU treatment was performed as an outpatient procedure under conscious sedation. Exclusion criteria were pregnant or lactating women, microcalcifications within the lesion at mammogram, history of breast cancer, previous laser or radiation therapy, and breast implant in the same breast. All patients signed written informed consent. After the treatment, follow-up US with volume evaluation was performed at 2, 6, and 12 months. The FA mean baseline volume was 3.89 ml (0.34–19.66 ml). At 2-month follow-up, the mean volume reduction was 33.2% ± 19.1% and achieved significance at 6-month (59.2% ± 18.2%, p < 0.001) and 12-month (72.5% ± 16.7%, p < 0.001) follow-up. Related side effects as superficial skin burn with blister-like aspect in three patients and hyperpigmentation over the treated area in one patient were transient and resolved spontaneously. In one patient, asymptomatic subcutaneous induration persisted at the end of the study. US-guided HIFU treatment is an effective noninvasive method for the treatment of breast FA and well tolerated by the patients. Preliminary results are encouraging and show that HIFU could be an alternative to surgery for breast FA.

1 August 2015 in Radiology
Verified
Journal Article
Closed access
RKRoussanka D. Kovatcheva
Roussanka D. Kovatcheva
JVJordan D. Vlahov
Jordan D. Vlahov
JSJulian I. Stoinov
Julian I. Stoinov
KZKatja Zaletel
Katja Zaletel
To assess the short-term efficacy and safety of ultrasonographically (US)-guided high-intensity focused ultrasound (HIFU) ablation for treatment of benign solid thyroid nodules. This prospective study was approved by the institutional ethics committee, and written informed consent was acquired. HIFU ablation was performed in one session with US guidance and conscious sedation in 20 euthyroid patients (mean age, 44.5 years) with a benign solitary or dominant thyroid nodule. Thyroid nodule volume, US structure, and Doppler pattern were assessed at baseline, at 1 week, and at 1, 3, and 6 months after treatment. Adverse events associated with HIFU were evaluated. Statistical analysis was conducted by using repeated measures analysis of variance, the Student t test, χ(2) test, and correlation analysis. The mean ± standard deviation nodule volume was 4.96 mL ± 2.79 at the start of the study. Nodule volume had decreased to 3.05 mL ± 1.96 at the 3-month follow-up examination (n = 20, P < .001), and reached 2.91 mL ± 2.43 by the 6-month follow-up examination (n = 16, P < .001). By then, the mean volume reduction was 48.7% ± 24.3 (P < .001). Isoechoic nodules showed greater reduction at 1 month than did hypoechoic nodules (31.6% ± 18.1 vs 16.4% ± 8.6, P = .053). Nodules with markedly increased blood flow showed smaller volume reduction at 3 months than did less-vascularized nodules (10.9% ± 14.5 vs 41.5% ± 20.3, P = .054). Minor transient complications (eg, subcutaneous edema, mild skin redness) were observed in two patients. Early data suggest that US-guided HIFU ablation is an effective and safe procedure for treatment of benign solid thyroid nodules. Initial US echogenicity and vascularization influence the ablation outcome.

4 June 2014 in European Radiology
Verified
Journal Article
Closed access
PDF file
RKRoussanka Kovatcheva
Roussanka Kovatcheva
JVJordan Vlahov
Jordan Vlahov
JSJulian Stoinov
Julian Stoinov
FLFrancois Lacoste
Francois Lacoste
COCatherine Ortuno
Catherine Ortuno
KZKatja Zaletel
Katja Zaletel

5 December 2017 in Postgraduate Medicine
Verified
Journal Article
Closed access
ASAlexander Shinkov
Alexander Shinkov
ABAnna-Maria Borissova
Anna-Maria Borissova
RKRoussanka Kovatcheva
Roussanka Kovatcheva
JVJordan Vlahov
Jordan Vlahov
LDLilia Dakovska
Lilia Dakovska
PPPaulina Petkova
Paulina Petkova
Objectives: The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors associated with high cardiovascular morbidity and mortality. The MetS and its elements have been linked to anxiety and depressive disorders. The aim of the current cross-sectional study was to assess the prevalence of depression and anxiety, measured by the Zung Self-Rating Scale in subjects with and without the metabolic syndrome and diabetes. Methods: A total of 2111 adults were included, 1155 female, age 47.6 (13.7) and 956 male, age 45.2 (13.5). All participants filled questionnaires covering current and past disorders and medication, smoking and family history. Zung self-rating depression and anxiety scales were completed. Body weight, height and waist circumference were measured, BMI was calculated, serum glucose and lipids were measured. Results: Depression (SDSi) and anxiety scores (SASi) were higher in the females and increased with age (p < 0.001). SDSi was higher in the females and males with metabolic syndrome (MetS) (50.9 ± 9.8 vs. 45.9 ± 8.9, p < 0.001 and 42.7 ± 9.2 vs. 40.5 ± 7.9 p < 0.001, respectively). SASi was higher in the MetS subjects (females 50.59 ± 11.35 vs. 45.97 ± 10.58, p < 0.001; males 40.48 ± 10.1 vs. 38.04 ± 8.42, p < 0.001). Both SDSi and SASi were higher in the subjects with known diabetes than in those with normal glucose tolerance (Mann-Whitney both p < 0,001). Positive depressive scores were more prevalent in subjects with MetS than those without (females 54% vs. 31.6%, p < 0.001; males 22.7% vs. 12.3%, p < 0.001). Depression and anxiety were more prevalent in the subjects with known diabetes than in those with normal glucose tolerance but not in the newly-diagnosed diabetes. The OR for depressiveness was 2.0 (1.3; 2.6) in subjects with MetS and 4.2 (2.3; 7.8) in those with known diabetes. Conclusions: In conclusion, depressiveness and anxiety were associated positively with age and female gender and were more prevalent among subjects with MetS and known diabetes mellitus.

1 October 2010 in American Journal of Roentgenology
Verified
Journal Article
Closed access
RKRoussanka D. Kovatcheva
Roussanka D. Kovatcheva
JVJordan D. Vlahov
Jordan D. Vlahov
ASAlexander Shinkov
Alexander Shinkov
ABAnna-Maria Borissova
Anna-Maria Borissova
JHJoo Ha Hwang
Joo Ha Hwang
LHLaszlo Hegedüs
Laszlo Hegedüs
OBJECTIVE. Many patients with primary hyperparathyroidism either decline or are not candidates for surgical parathyroidectomy. There are drawbacks to medical therapy as well as percutaneous ethanol injection as alternative therapies for primary hyperparathyroidism. Therefore, in this pilot study, our aim was to test the feasibility, safety, and efficacy of a newly developed noninvasive high-intensity focused ultrasound (HIFU) technique for the nonsurgical management of primary hyperparathyroidism.SUBJECTS AND METHODS. We treated four menopausal women with biochemical, sonographic, and cytologic evidence of benign primary hyperparathyroidism. HIFU treatment was performed in two sessions using TH-One under sonographic guidance and with the patient under conscious sedation. Parathyroid volume and function were evaluated at baseline and repeatedly until 12 months after the second HIFU session.RESULTS. Serum parathyroid hormone levels decreased in all four patients and normalized 1 and 8 months after the secon...

16 March 2017 in Journal of Therapeutic Ultrasound
Verified
Journal Article
Open access
PDF file
RKRoussanka Kovatcheva
Roussanka Kovatcheva
KZKatja Zaletel
Katja Zaletel
JVJordan Vlahov
Jordan Vlahov
JSJulian Stoinov
Julian Stoinov
To assess the long term efficacy and tolerability of one or two ultrasound (US)-guided high-intensity focused ultrasound (HIFU) treatment in patients with breast fibroadenoma (FA). Twenty patients with 26 FA were selected for US-guided HIFU. The therapy was performed in one or two sessions. FA volume was assessed before and followed up to 24 months after the last HIFU. After each treatment, adverse events were evaluated. In 19/26 FA (73.1%) one HIFU was performed (group 1), whereas 7/26 FA (26.9%) received second HIFU (group 2) 6-9 months (median, 7 months) after the first session. In group 1 and 2, FA volume decreased significantly at 1-month (p < 0.001) and 3-month follow-up (p = 0.005), respectively, and continued to reduce until 24-month follow-up (p < 0.001 and p = 0.003, respectively). At 24 months, mean volume reduction was 77.32% in group 1 and 90.47% in group 2 (p = 0.025). Mild subcutaneous edema was observed in 4 patients and skin erythema in 3 patients. US-guided HIFU represents a promising non-invasive method with sustainable FA volume reduction and patient’s tolerability. Although one treatment is highly efficient, the volume reduction can be increased with second treatment. NCT01331954 . Registered 07 April 2011.